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Abstract
The sensitivity of cells to death receptor-induced apoptosis is commonly controlled by multiple checkpoints in order
to limit induction of excessive or unnecessary death. Although cytotoxic in various cancer cells, tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) does not trigger apoptosis in most non-transformed cells. The
molecular nature of the checkpoints that normally protect the cells from TRAIL-induced death are not fully
understood. Endoplasmic reticulum (ER) stress has been reported to switch the sensitivity of human cells to the
cytotoxic effect of TRAIL, suggesting that this cellular state perturbs some of these protective mechanisms. We found
that tunicamycin (TU), but no other ER stress inducers, sensitized mouse ﬁbroblasts and hippocampal neuronal cells to
TRAIL-induced apoptosis. Importantly, the sensitization was speciﬁc to TRAIL and not caused by differences in ER stress
induction. Instead, it relied on the inhibition of N-glycosylation of the mouse TRAIL receptor (mTRAIL-R). Inhibition of
N-glycosylation did not alter cell surface expression of mTRAIL-R but enhanced its ability to bind TRAIL, and facilitated
mTRAIL-R oligomerization, which resulted in enhanced death-inducing signaling complex (DISC) formation and
caspase-8 activation. Remarkably, reconstitution of mTRAIL-R-deﬁcient cells with a version of mTRAIL-R mutated for the
three N-glycosylation sites identiﬁed in its ectodomain conﬁrmed higher sensitivity to TRAIL-induced apoptosis.
Together, our results demonstrate that inhibition of N-glycosylation of mTRAIL-R, and not ER stress induction, sensitizes
mouse cells to TRAIL-induced apoptosis. We therefore reveal a new mechanism restraining TRAIL cytotoxicity in
mouse cells.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a member of the TNF family
that has the ability to drive NF-κB-dependent expression
of pro-inﬂammatory mediators and/or trigger apoptosis
upon binding to its cognate receptors hTRAIL-R1 and
hTRAIL-R2 (also known as DR4 and DR5, respectively) in
human, or mTRAIL-R in mouse1–5. Apoptosis is not the
default response of most cells to TRAIL, but occurs in
various types of cancer cells6,7. This selective cytotoxicity
has generated hope for the use of TRAIL as anti-cancer
agent. Nevertheless, many tumor cells remain refractory
to apoptosis induced by TRAIL, and ways to sensitize
these transformed cells to the pro-apoptotic effect of this
cytokine are currently under investigation8–10.
The reason why certain cancer cells spontaneously die
upon TRAIL sensing is not fully understood, but indicates
that these cells have lost some of the protective
mechanisms that normally inhibit or restrain apoptosis
induction. TRAIL-R-induced apoptosis relies on the
binding of the adapter molecule Fas-associated death
domain (FADD) to the intracellular portion of the
receptor for the further recruitment of caspase-8. Within
the generated death-inducing signaling complex (DISC),
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caspase-8 undergoes autocatalytic processing, which
results in the release of its active form in the cytoplasm
where it cleaves and activates the effector caspases-3 and
-7, ultimately leading to the dismantlement of the cell1,11.
This extrinsic TRAIL-R-induced apoptotic trigger can be
ampliﬁed by engagement of the intrinsic apoptotic path-
way via caspase-8-dependent activation of Bid, a proa-
poptotic Bcl-2 family member12–14. Low concentration of
the translation inhibitor cycloheximide (CHX) is com-
monly used to switch the TRAIL response from survival
to death in human- and mouse-resistant cells, indicating
that TRAIL-induced apoptosis is normally actively
repressed by proteins of short half-lives and/or translated
in response to TRAIL sensing. The cellular expression of
the caspase-8 homolog FLICE-inhibitory protein (cFLIP),
which can be induced by NF-κB activation, appears to
greatly inﬂuence the sensitivity of the cells to the proa-
poptotic effect of TRAIL15,16, similarly as for other death
ligands of the TNF family. Indeed, cFLIP repression was
shown to be sufﬁcient to switch the TRAIL response to
death in resistant cells of both normal and cancerous
origin17–19. In addition to the translational control of
cFLIP and other agonistic/antagonistic proteins, the sen-
sitivity to TRAIL is also inﬂuenced by post-translational
modiﬁcations. Among them, O-glycosylation of hTRAIL-
R1 and hTRAIL-R2 is proposed to sensitize cancer cells to
TRAIL-induced apoptosis by facilitating clustering of the
receptors and, consequently, DISC assembly20.
Sensitization to TRAIL-induced apoptosis is also fre-
quently reported in human cells undergoing endo-
plasmic reticulum (ER) stress, a cellular state of distress
caused by accumulation of un- or misfolded proteins in
the ER lumen. The unfolded-protein response (UPR), an
integrated signaling network activated by eukaryotic
cells in response to ER stress, initially aims at restoring
protein homeostasis by reducing the protein load, but
turns into a toxic signal triggering death when the cell is
unable to cope with the severity of the stress21.
Although the mechanism by which ER stress sensitizes
human cells to TRAIL-induced apoptosis remains con-
troversial, some studies explain it by the UPR-
dependent downregulation of cFLIP and/or upregula-
tion of hTRAIL-R1/222–28. Apart from switching the
sensitivity of human cells to the cytotoxic effect of
TRAIL, the upregulation of hTRAIL-R2 by the UPR is
also proposed to cause ligand-independent receptor
clustering, DISC formation, and apoptosis induction in
human cells undergoing unresolved ER stress29–32. In
contrast with these later ﬁndings, we previously repor-
ted that mTRAIL-R is dispensable for ER stress-induced
death in mouse embryonic ﬁbroblast (MEFs)33, thereby
questioning the general and/or conserved aspect of the
ER stress-induced death mechanism described in human
cells.
In this study, we found that tunicamycin (TU), but no
other ER stress inducer, confers sensitivity of MEFs,
mouse 3T3 ﬁbroblasts, and HT-22 hippocampal neu-
ronal cells to TRAIL-induced death. Importantly, we
show that the sensitization is unrelated to ER stress
induction, but instead originates from inhibition of N-
glycosylation of mTRAIL-R. Our study therefore high-
lights differences in the sensitization of human and
mouse cells to TRAIL-induced apoptosis in the context
of ER stress, and reveals a new post-translational
mechanism restraining TRAIL cytotoxicity in cells of
mouse origin.
Results
Tunicamycin speciﬁcally sensitizes mouse cells to TRAIL-
induced apoptosis
Previous studies have reported that UPR-mediated
upregulation of hTRAIL-R1 and hTRAIL-R2 can induce
apoptosis in human cells by promoting hTRAIL-R2
clustering independently of TRAIL sensing, or by sen-
sitizing the cells to the cytotoxic effect of TRAIL22,24–
30,32. In contrast to these ﬁndings, we previously showed
that mTRAIL-R is dispensable for ER stress-induced
apoptosis in MEFs33. In order to test whether MEFs can
still be sensitized to TRAIL under ER stress conditions,
we stimulated the cells with TRAIL in the absence or
presence of TU, a classical ER-stress inducer. Remark-
ably, while the MEFs were completely resistant to
TRAIL used alone, its co-stimulation with TU greatly
sensitized the cells to TRAIL-induced apoptosis, as
monitored by plasma membrane permeabilization
(Fig. 1a), caspase-8 and -3 processing (Fig.1b), and cell
death inhibition in presence of the pan caspase inhibitor
zVAD-fmk (Fig. 1c). The sensitization was dose
dependent, both when using recombinant mouse
SuperKillerTRAIL™ (mTRAIL-SK) or a less stable
TRAIL ligand (mTRAIL) (Fig. 1d, e). Surprisingly,
TRAIL-induced apoptosis was not observed when co-
stimulating the cells with thapsigargin (THAP) (Fig. 1f)
or brefeldin A (BFA) (Fig. 1g), despite their comparable
potency at inducing the classical ER stress markers
Chop, Bip, and the spliced form of Xbp1 (Fig. 1h).
Importantly, TU treatment did not sensitize MEFs to
TNF (Fig. 1i), indicating that TU did not confer general
sensitization of mouse cells to death ligands of the TNF
family. In line with previous studies34–36, we however
found that TU also sensitized MEFs to Fas ligand (FasL)
(Fig. 1j), which therefore served as a positive control in
the experiment. Of note, CHX sensitized the cells to
death in response to FasL, TNF, and TRAIL, but the
sensitizing effect appeared stronger for FasL and TNF
(Fig. 1i, j).
The speciﬁc sensitization to TRAIL-induced apoptosis
by TU was not limited to MEFs but also observed in
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mouse HT-22 hippocampal neuronal cells (Fig. 1k) and
3T3 ﬁbroblasts (Fig. 1l). This situation contrasted with
the reported ER stress-dependent sensitization to
TRAIL in human cells and that we conﬁrmed in Hela
and NCI-H292 cancer cells (Suppl. Figure 1a-b) as well
as in nonmalignant nasopharyngeal NP69 cells (Suppl.
Figure 1c). Taken together these results reveal that TU
can sensitize mouse cells to TRAIL-induced apoptosis
independently of ER-stress induction, and highlight
differences between human and mouse TRAIL-R sig-
naling that cannot be explained by the malignant state of
the cells.
Fig. 1 (See legend on next page.)
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TU induces appearance of a non-N-glycosylated form of
mTRAIL-R
TU is an inhibitor of N-glycosylation, which let us
hypothesize that the sensitizing effect of TU was originating
from defective N-glycosylation. The fact that TU did not
sensitize cells to TNF also suggested that it was affecting
speciﬁc component(s) of the TRAIL signaling pathway. In
line with this idea, we found that TU led to the appearance
of a non-N-glycosylated form of mTRAIL-R. Indeed, TU
treatment induced a mobility shift of mTRAIL-R that
resulted in the detection of a sharp 40 kDa band instead of a
diffuse signal around 50 kDa in control and THAP condi-
tions (Fig. 2a). We conﬁrmed that both signals were speciﬁc
to mTRAIL-R by siRNA-mediated knockdown of the
receptor (Fig. 2b) and demonstrated the non-N-glycolysated
nature of the 40 kDa band by PNGase F treatment (an
amidase that removes all N-glycans). Indeed, similar
migration of mTRAIL-R was observed following TU treat-
ment or digestion with PNGase F, and no further mobility
shift was obtained when PNGase F was added to the TU-
treated cell lysates (Fig. 2c). Full kinetics of TU stimulation
indicated that the progressive loss of N-glycosylated
mTRAIL-R was accompanied by the appearance of the de
novo synthesized non-N-glycosylated receptor, which
became predominant in the cell lysate starting around 6 h
post stimulation (Fig. 2d).
Non-N-glycosylated mTRAIL-R is expressed at the plasma
membrane where it exhibits higher binding capacity for
TRAIL
N-glycosylation supports the correct folding of pro-
teins and is required for proteins to adopt their
functional tertiary structures before reaching ﬁnal
destination37,38. In order to test whether the detected
non-N-glycosylated mTRAIL-R is functional and
expressed at the plasma membrane, we ﬁrst compared
cell surface expression of mTRAIL-R in control con-
ditions and after 7 h of TU treatment, a timing at which
cells predominantly expressed non-N-glycosylated
mTRAIL-R (Figs. 2d, 3b). As shown in Fig. 3a, both N-
glycosylated and non-N-glycosylated forms of the
receptor were similarly expressed at the plasma mem-
brane (Fig. 3a). Thus, non-N-glycosylated mTRAIL-R
passes the quality control of protein folding in the ER
and is properly addressed to the plasma membrane.
The ability of the non-N-glycosylated receptor to sense
TRAIL was then evaluated by performing a kinetic
analysis of His-tag mTRAIL pulldowns in cells pre-
stimulated, or not, with TU for 7 h. The fact that N-
glycosylated mTRAIL-R appears as a diffuse signal
around 50 kDa while non-N-glycosylated mTRAIL-R is
detected as a sharp 40 kDa band renders difﬁcult the
comparison of the binding efﬁciencies of the two forms
of the receptor (Suppl. Figure 2). To circumvent this
problem, we treated the samples with PNGase F after
the pulldown, and then analyzed them by immunoblot
in non-reducing conditions. We indeed noticed that
the anti-mTRAIL antibody used recognizes an epitope
that is partially lost under reducing conditions (Suppl.
Figure 2). By this methodological approach, we
observed earlier and stronger binding of mTRAIL to
the non-N-glycosylated form of mTRAIL-R, indicating
a better afﬁnity of non-N-glycosylated receptor for its
ligand (Fig. 3b).
Fig. 1 Tunicamycin speciﬁcally sensitizes mouse cells to TRAIL-induced apoptosis. a Cell death proﬁles of MEFs treated with 20 ng/ml
recombinant mouse SuperKillerTRAIL (mTRAIL SK), 1 μg/ml tunicamycin (TU), or the combination of both. The percentage of cell death was measured
over time using a Fluostar Omega ﬂuorescence plate reader analyzing the SYTOX Green-positive cells. Error bars represent S.E.M. of three
independent experiments. *P < 0.05; **P < 0.01. b MEFs were stimulated with TU in presence or absence of 20 ng/ml mTRAIL-SK for 15 h, and cell
lysates were immunoblotted as indicated. Caspase cleavage products are indicated by arrowheads. Representative images of two independent
experiments. c Cell death proﬁle of MEFs pretreated with 20 μM Z-VAD-FMK (Z-VAD) or control (CTRL) followed by treatment with either mTRAIL-SK
(20 ng/ml), TU, or TU+mTRAIL-SK for 18 h. Cell death was measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of
two independent experiments. d Cell death proﬁles of MEFs stimulated with TU in combination or not with increasing doses (6, 20, and 200 ng/ml) of
mTRAIL SK or mTRAIL for 20 h. Cell death was measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of two
independent experiments. e Cell death proﬁles of MEF cells stimulated with 20 ng/ml mTRAIL-SK in combination or not with increasing doses of TU
for 20 h. Cell death was measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of two independent experiments. f, g
Cell death proﬁles of MEFs exposed to f 1 μM thapsigargin (THAP) or THAP+ 20 ng/ml mTRAIL-SK; or g 0.5 μM brefeldin A (BFA) or BFA+ 20 ng/ml
mTRAIL-SK for 16 h and 20 h. Cell death was measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of three
independent experiments. h MEFs were incubated with TU, THAP, or BFA for 4 and 6 h, and cell lysates were immunoblotted as indicated.
Representative images of two independent experiments. i Cell death proﬁles of MEFs exposed to TU or 1.5 μg/ml translation inhibitor cycloheximide
(CHX) in combination or not with 20 ng/ml of human (h) or mouse (m) TNF for 20 h. Cell death was measured using a Fluostar Omega ﬂuorescence
plate reader. Error bars represent S.E.M. of two independent experiments. j Cell death proﬁles of MEFs exposed to TU or 1.5 μg/ml CHX in
combination or not with 20 ng/ml mTRAIL-SK or hFas Ligand (hFasL) for 16 h. Cell death was measured using a Fluostar Omega ﬂuorescence plate
reader. Results are representative of two independent experiments. Error bars represent S.E.M. of triplicates from a representative experiment. k Cell
death proﬁles of HT22 cells treated for 24 h with 20 ng/ml mTRAIL-SK, or with TU or THAP in combination or not with mTRAIL-SK. Cell death was
measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of two independent experiments. l Cell death proﬁles of 3T3
cells treated with mTRAIL-SK or with TU or THAP, in combination or not with mTRAIL-SK. Cell death was measured using an Incucyte ZOOM® system.
Results are representative of two independent experiments. Error bars represent S.E.M. of duplicates from a representative experiment
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Non-N-glycosylated mTRAIL-R triggers ligand-dependent
apoptosis in TU-treated cells
The results obtained so far indicate that TU-
dependent sensitization to TRAIL-induced apoptosis is
associated with plasma membrane exposure of a non-N-
glycosylated form of mTRAIL-R, but whether this
modiﬁed receptor plays any role in TRAIL sensitization
is currently unknown. To evaluate this possibility, we
pretreated MEFs for 6 h with TU to induce full con-
version of mTRAIL-R to its non-N-glycosylated state,
and then tested the response of the cells to TRAIL sti-
mulation. Remarkably, processing of caspase-8 was
detected after only 2 h of mTRAIL-SK stimulation in
the non-N-glycosylated mTRAIL-R-expressing cells
(Fig. 4a). Such a sensitization was not observed in cells
pretreated for 6 h with THAP or CHX (Fig. 4a),
Fig. 2 Tunicamycin induces appearance of a non-N-glycosylated form of mTRAIL-R. a MEFs were treated with CTRL, TU, or THAP for 17 h, and
cell lysates were immunoblotted for mTRAIL-R and β-tubulin. Asterisk indicates non-speciﬁc signal. Representative images of three independent
experiments. b MEFs were transfected with non-silencing (NS) or mTRAIL-R speciﬁc siRNA, and then treated with TU for 17 h. Cell lysates were
immunblotted for mTRAIL-R and β-tubulin. Asterisk indicates non-speciﬁc signal. Representative images of three independent experiments. c Cell
lysates of CTRL- or TU-treated MEFs were incubated at 37 °C for 1 h in presence or absence of PNGase F (PNG), and then immunoblotted for mTRAIL-
R and β-tubulin. Asterisk indicates non-speciﬁc signal. Representative images of two independent experiments. d MEF cells were treated with TU for
increasing times and cell lysates were immunblotted for mTRAIL-R and β-tubulin. Asterisk indicates non-speciﬁc signal. Representative images of
three independent experiments
Fig. 3 Non-N-glycosylated mTRAIL-R is expressed at the plasma membrane where it exhibits higher binding capacity for TRAIL. a Cell
surface expression of mTRAIL-R in MEFs treated for 7 h with CTRL or TU, and analyzed by ﬂow cytometry using a FACSVerse cytometer. Isotype-PE
(ﬁlled histogram), mTRAIL-PE (open histogram). Representative histogram of three independent experiments. b Immunoblots under non-reducing
conditions of mTRAIL-R of a His-Tag pulldown on MEFs pre-treated with TU or control for 7 h followed by mTRAIL-SK (500 ng/ml) treatment for
increasing times. Before loading, pulldown samples were treated (+PNG) or not with PNGase F in non-reducing conditions. Representative images of
at least two independent experiments
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Fig. 4 Non-N-glycosylated mTRAIL-R triggers ligand-dependent apoptosis in tunicamycin-treated cells. a MEFs were treated for 6 h with
control or TU followed by stimulation with mTRAIL-SK (20 ng/ml) for the indicated times. Cell lysates were then immunoblotted as indicated.
Caspase-8 and c-FLIP cleavage products are indicated by arrowheads. Asterisk indicates non-speciﬁc signal. Representative images of three
independent experiments. b MEFs were exposed to TU or control for 7 h followed by Biotin-ILZ-hTRAIL (biot-ILZ-hTRAIL) (500 ng/ml) or CTRL
treatment for 15 min. Cell lysates were subjected to streptavidin (Strep) pulldown and immunoblotted for mTRAIL-R and FADD under non-reducing
conditions. Left panels: Strep pulldown. Right panels: Input. HMW high molecular weight. Representative images of two independent experiments. c
MEFs were exposed to TU or control for 7 h followed by mTRAIL-SK (20 ng/ml) or CTRL treatment for 2 h. Cell lysates were subjected to FADD
immunoprecipitation (IP:FADD) and immunoblotted as indicated. mTRAIL-R was detected under non-reducing conditions. Left panels: IP:FADD. Right
panels: Input. Caspase-8 cleavage products are indicated by arrowheads. HMW high molecular weight. Asterisk indicates non-speciﬁc signal.
Representative images of two independent experiments
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supporting the idea of increased cytotoxic potential of
non-N-glycosylated mTRAIL-R.
Galectins bind N-acetyllactosamine present on
complex-type N-glycans39, and Galectin-3 has been
reported to negatively regulates TRAIL-induced death in
human cancer cells, potentially by binding to hTRAILR1/
R2 and altering their ligand-dependent internalization40.
To test whether inhibition of mTRAIL-R N-glycosylation
by TU releases an inhibitory role of galectins on mTRAIL-
R, we stimulated the cells with kifunensine and swainso-
nine, respectively mannosidase I and II inhibitors that lead
to the accumulation of proteins harboring high mannose-
type N-glycans devoid of N-acetyllactosamine. In contrast
to TU, neither kifunensine nor swainsonine sensitized
MEFs to mTRAIL-SK-mediated cell death (Suppl. Fig-
ure 3a-b), indicating that the sensitization to TRAIL
killing induced by inhibition of N-glycosylation of
mTRAIL-R does not originate from impairment of
galectins binding to mTRAIL-R N-glycans.
TRAIL-induced apoptosis relies on ligand-dependent
receptor oligomerization, DISC formation, and auto-
activation of caspase-8 within the DISC. We then ana-
lyzed DISC assembly by TRAIL pulldowns in MEFs pre-
treated or not with TU for 6 h (Fig. 4b, c). Interestingly,
binding of TRAIL to the two versions of mTRAIL-R led to
the detection, in non-reducing conditions, of high mole-
cular weight (HMW) forms of the receptor that had dif-
ferent proﬁles. While N-glycosylated mTRAIL-R formed a
single prominent oligomer at around 95 kDa, non-N-gly-
cosylated mTRAIL-R was present in several oligomeric
conformers with major bands detected around 80, 90, and
120 kDa (Fig. 4b). Non-N-glycosylated mTRAIL-R also
recruited more FADD than its N-glycosylated counter-
part, despite apparent similar efﬁciency in the amount of
receptor pulled-down by the biotinylated Isoleucine Zip-
per (biot-ILZ) hTRAIL (Fig. 4b). Under similar condi-
tions, FADD immunoprecipitation conﬁrmed the
increased association of FADD with non-N-glycosylated
mTRAIL-R in response to mTRAIL-SK (Fig. 4c). Taken
together these results indicate that in TU-treated MEFs,
TRAIL-induced apoptosis is driven by a non-N-glycosy-
lated form of mTRAIL-R that appears to have distinct
oligomerization capacities and enhanced cytotoxic
potential.
mTRAIL-R is N-glycosylated on three asparagine residues
in its ectodomain
In silico analysis of the mTRAIL-R sequence with
NetGlyc 1.0 predicted existence of three N-glycosylation
sites on the ectodomain of the receptor, on Asparagine
(N) residues N99, N122, and N150 (Fig. 5a). To test the
presence of N-glycans on these potential acceptor resi-
dues, we mutated each of them separately and together,
and then overexpressed the obtained mutants in Trail-R−/−
MEFs by transient transfection (Fig. 5b, c). We chose to
perform Asparagine to Glutamine substitutions (N >Q) to
Fig. 5 mTRAIL-R is N-glycosylated on three asparagine residues in its ectodomain. a Schematic presentation of the three putative N-
glycosylation sites (NetGlyc 1.0 prediction) in the extracellular domain of mTRAIL-R. b Trail-R−/− MEFs were transiently transfected with an empty
vector (EV), wild-type (WT) mTRAIL-R, or N-glyc mTRAIL-R mutants pcDNA3 plasmids for 24 h, and cell lysates were immunoblotted for mTRAIL-R.
Representative images of three independent experiments. c Trail-R−/− MEFs were transiently transfected with an EV, WT mTRAIL-R, or N-glyc mTRAIL-
R mutants pcDNA3 plasmids for 24 h in absence (CTRL) or presence of TU, and cell lysates were immunoblotted for mTRAIL-R. Representative images
of three independent experiments
Estornes et al. Cell Death and Disease  (2018) 9:494 Page 7 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
maintain the polar character of the amino acid. Analysis
of the migration proﬁles of the different mutants by
reducing SDS PAGE revealed N-glycosylation of
mTRAIL-R on each of the predicted sites (Fig. 5b).
Importantly, only the triple N99/N122/N150Q mutant
had a similar migration pattern as the non-N-glycosylated
receptor generated by TU/PNGase F treatment
(Figs. 5c, 2c), thereby demonstrating absence of additional
N-glycosylation site in mTRAIL-R.
N-glycosylation of mTRAIL-R restrains apoptosis induction
Transient overexpression of death receptors often trig-
gers ligand-independent death due to spontaneous
aggregation of the receptors2–4. We observed that over-
expression of N99/N122/N150Q mTRAIL-R in Trail-R−/−
MEFs resulted in increased ligand-independent apoptosis
when compared to overexpression of WT mTRAIL-R
(Fig. 6a and Suppl. Figure 4a). Of note, no sign of ER stress
was detected in cells overexpressing WT or non-N-glyco-
sylated mTRAIL-R (Suppl. Figure 4b). The difference in cell
death induction was not originating from higher expression
of the mutated receptor since cell surface staining showed
similar percentages of cells expressing both forms of the
receptor, and the mean intensity of the signal was even
weaker for the N99/N122/N150Q mTRAIL-R-expressing
cells (Suppl. Figure 4c-e). This was conﬁrmed by comparing
the expression of the two forms of mTRAIL-R by immu-
noblot in reducing conditions (Fig. 6b). However, analysis of
the cell lysates in non-reducing conditions revealed clear
differences in the oligomeric state of the receptor. WT
mTRAIL-R oligomerized into several species of variable
sizes, which resulted in the detection of a smear starting at
around 90 kDa. In contrast, the N99/N122/N150Q
mTRAIL-R mutant was mainly detectable at the interface
between the stacking and the running part of the gel, or as a
light signal corresponding to the monomeric form of the
receptor, indicating a differential oligomerization potential
into HMW complexes (Fig. 6b). To overcome the problem
of spontaneous cell death induction, we next stably recon-
stituted the Trail-R−/− MEFs with a Tet-on lentiviral sys-
tem for doxycycline(dox)-inducible expression of WT
(iWT) and iN99/N122/N150Q mTRAIL-R, which allowed
lower expression level of mTRAIL-R (Fig. 6c). In order to
reach similar expression level of WT vs N99/N122/N150Q
mTRAIL-R, dox concentration was lowered from 1000 to
50 ng/ml for the iWT mTRAIL-R-reconstituted cells
(Fig. 6c). Surprisingly, stimulation with mTRAIL-SK did not
induce apoptosis, monitored by plasma membrane per-
meabilization and caspase-3 activity, in the iN99/N122/
N150Q mTRAIL-R-expressing cells (Fig. 6d, e). This sug-
gests that the sensitization caused by TU treatment in
WT cells does not solely originate from the expression of
the non-N-glycosylated mTRAIL-R. Alternatively, the
absence of cell death induction could also result from the
too low expression level of exogenous iN99/N122/N150Q
mTRAIL-R. Because sensitization to TRAIL can be
achieved by pretreatment with CHX16, we next evaluated
the effect of inhibiting N-glycosylation of mTRAIL-R under
these sensitizing conditions. Remarkably, mTRAIL-SK-
induced apoptosis was much higher in the iN99/N122/
N150Q mTRAIL-R-expressing cells (Fig. 6d, e), thereby
further demonstrating the role of N-glycosylation of
mTRAIL-R in restraining its cytotoxic potential. Together,
our results demonstrate that N-glycosylation of mTRAIL-R
in its ectodomain constitutes one of the mechanisms
restraining the cytotoxic effect of TRAIL in murine cells.
Discussion
Although cytotoxic in various human cancer cells,
TRAIL does not trigger apoptosis in most non-
transformed cells. Sensitization of resistant cells to
TRAIL-induced apoptosis is generally obtained by co-
stimulation with the translation inhibitor cycloheximide,
and is believed to be caused, at least in part, by the
inhibition of cFLIP translation16. The state of ER stress
has also been reported to sensitize human cancer cells to
the cytotoxic effect of TRAIL. Under these conditions, the
sensitization is mainly reported to originate from upre-
gulation of hTRAIL-R222–28. We conﬁrmed the ER stress-
associated sensitization of human cells to TRAIL-induced
apoptosis and showed that this effect was not speciﬁc to
cancer cells. We found that resistant non-cancerous
mouse cells can also be sensitized to TRAIL cytotoxicity
when co-stimulated with the ER stress inducer TU.
However, in clear contrast with the human situation, the
sensitization was not caused by ER stress since neither
thapsigargin nor brefeldin A reproduced the sensitization.
The effect was also not the result of mTRAIL-R upregu-
lation, but instead caused by expression of a non-N-gly-
cosylated form of the receptor. We found that mTRAIL-R
is N-glycosylated on three Asparagine resides (N99, N122,
and N150) of its ectodomain, and demonstrated the
protective effect of these post-translational modiﬁcations
by reconstituting mTRAIL-R-deﬁcient cells with the non-
N-glycosylated mutated receptor. Since mTRAIL stimu-
lation in MEFs did not lead to detectable activation of the
NF-κB and MAPK pathways (Suppl. Figure 5a-b), it is
reasonable to think that the sensitization to TRAIL killing
induced by inhibition of N-glycosylation of mTRAIL-R
does not originate from alteration of NF-κB or MAPK
activation.
In human cells, TRAIL can trigger apoptosis by binding
to hTRAIL-R1 and hTRAIL-R2. The sensitizing effect of
TU to TRAIL-induced apoptosis has been attributed to
the induced expression of hTRAIL-R2, but the implica-
tion of hTRAIL-R1 is less established. In contrast to
hTRAIL-R2, hTRAIL-R1 also contains a N-glycosylation
site in its ectodomain. Indeed, treatment of various
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human cancer cells with TU results in the detection of a
faster migrating form of hTRAIL-R1, indicative of inter-
ference with the N-glycosylation pattern of hTRAIL-R1,
but its upregulation is only reported in a limited number
of sensitized cells24,2628,30,41. It is therefore possible that
inhibition of N-glycosylation by TU also generates a non-
N-glycosylated hTRAIL-R1 with increased cytotoxic
potential.
Surprisingly, a recent study reports that N-glycosylation
of hTRAIL-R1 on N156 or of mTRAIL-R on N99/N122/
N150 sensitizes rather than protects cells from TRAIL-
induced apoptosis42. These results clearly contrast with
our ﬁndings on mTRAIL-R, and the precise reason for the
apparent discrepancy remains unclear. Differences
between the cellular systems used in the two studies
should, however, be pointed out. We demonstrated the
effect of N-glycosylation of mTRAIL-R by reconstituting
mTRAIL-R-deﬁcient cells with the non-N-glycosylated
mutant, thereby excluding any possible interference with
endogenous mTRAIL-R. Importantly, our genetic results
are also supported by the pharmacological inhibition of
N-glycosylation by TU, whose sensitization to TRAIL-
induced apoptosis is triggered by non-N-glycosylated
mTRAIL-R.
Our results demonstrate a synergistic effect between TU
and TRAIL, and we explain it molecularly by the greater
Fig. 6 N-glycosylation of mTRAIL-R restrains apoptosis induction. a Trail-R−/− MEFs were transiently transfected with 300 ng of pcDNA3
plasmids coding for a wild-type (WT) mTRAIL-R, or non-N-glyc mTRAIL-R N99/122/150Q mutant. After 24 h, the percentage of double positive
mTRAIL-R+/Annexin V+ cells was analyzed by ﬂow cytometry using a FACSVerse cytometer. Error bars represent S.E.M. of four independent
experiments. *P < 0.05 in a ratio paired t test. b Trail-R−/− MEFs were transiently transfected with 300 or 600 ng of pcDNA3 plasmids coding for WT or
N99/122/150Q mutant mTRAIL-R. After 24 h, cell lysates were immunoblotted for mTRAIL-R in reducing vs non-reducing conditions. HMW high
molecular weight. Representative images of at least two independent experiments. c Trail-R−/− MEFs were stably transduced with viral particles
coding for an inducible wild-type (iWT) mTRAIL-R, or non-N-glyc mTRAIL-R N99/122/150Q mutant (iN99/122/150Q). The cells were treated with
doxycycline (Dox) at the indicated concentrations for 24 h, and cell lysates were immunoblotted for mTRAIL-R in non-reducing conditions and for
actin in reducing conditions. Representative images of three independent experiments. d, e Cell death (d) and caspase-3 activity (e) proﬁles of Trail-
R−/− MEFs transduced as in c, and then treated with mTRAIL-SK (20 ng/ml), cycloheximide (CHX; 0.250 μg/ml), or the CHX/mTRAIL-SK combination
for 24 h. Cell death and caspase-3 activity were measured using a Fluostar Omega ﬂuorescence plate reader. Error bars represent S.E.M. of three (d)
and two (e) independent experiments. **P < 0.01
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killing potential of non-N-glycosylated mTRAIL-R. As a
negative control, we used TNF to rule out the possibility
that TU induces synergistic killing with all death receptor
ligands (a situation observed for CHX). Fas/CD95 has
previously been reported to be N-glycosylated34,43, and we
found that TU also sensitized MEFs to FasL. However, in
contrast to TRAIL, CHX massively sensitized the cells to
death in response to FasL. These results may suggest that
the effect of TU on FasL-mediated killing is mainly caused
by alteration of prosurvival molecules expression. This
hypothesis could explain the controversial reported role
of N-glycosylation on the killing potential of Fas/CD9534–
36,43,44.
The addition of N-glycans onto a nascent polypetide
confers the protein with a polar character and also pro-
vides steric interference that inﬂuence inter- and intra-
molecular protein interactions to substantially modify the
structure and function of proteins37,38. N-glycans assist
the correct folding of newly synthesized proteins and is
required for proteins to adopt their functional tertiary
structures before reaching ﬁnal destination37,38. We found
that mTRAIL-R is N-glycosylated on three residues of its
ectodomain. Surprisingly, inhibition of N-glycosylation of
mTRAIL-R did not affect its exposure on the plasma
membrane but increased its ability to associate with
TRAIL. Further studies will be required to directly com-
pare these results with the reported non-altered binding
of TRAIL to non-N-glycosylated hTRAIL-R142. In addi-
tion, non-N-glycosylated mTRAIL-R showed differential
oligomerization potential associated with facilitated DISC
assembly. Analysis of the receptor by non-reducing SDS
PAGE revealed formation of SDS-detergent resistant,
HMW complexes stabilized by disulﬁde bonds. Since the
N-glycosylation sites of mTRAIL-R reside in proximity to
Cysteine residues, it is conceivable that the addition of N-
glycans sterically interferes with the formation of disulﬁde
bonds, thereby altering receptor oligomerization and
DISC assembly.
Our results suggest that TU-induced sensitization of
MEFs to TRAIL-mediated apoptosis is not solely origi-
nating from plasma membrane expression of non-N-gly-
cosylated mTRAIL-R. Indeed, TRAIL exposure was not
sufﬁcient to induce apoptosis in mTRAIL-R-deﬁcient
MEFs reconstituted with the non-N-glycosylated receptor.
Alternatively, this could be explained by the low level of
receptor expression in the reconstituted cells. Never-
theless, the protective role played by N-glycosylation was
demonstrated when TRAIL was combined to low levels of
cycloheximide. Indeed, under these sensitizing conditions,
apoptosis induction was much higher in the non-N-gly-
cosylated mTRAIL-R-expressing cells. These results
indicate that N-glycosylation of mTRAIL-R is probably
not the most limiting checkpoint in the apoptotic pathway
but serves to ﬁne-tune the sensitivity of the cells. Further
work will therefore be needed to identify the pathophy-
siological conditions that affect N-glycosylation of the
receptor.
Materials and methods
Cell cultures
Wild-type (WT) MEFs were isolated from E12.5 litter-
mate embryos and immortalized with SV40 large T
antigen, as previously described45. Trail-R−/− MEFs were
a kind gift of Dr. Mak (UHN, Toronto, Canada). MEF,
immortalized mouse hippocampal HT22, mouse ﬁbro-
blasts 3T3, and human cervix cancer HeLa cells were
cultured in high glucose Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal calf
serum and L-glutamine (200 mM). Human lung cancer
NCI-H292 were grown in RPMI 1640 medium supple-
mented with 10% fetal calf serum, HEPES, NaPy, and L-
glutamine (200 mM). Immortalized nonmalignant
human nasopharyngeal epithelial NP69 cells were grown
in KSFM supplemented with 10% FCS. The sequence
encoding WT mTRAIL-R was obtained from the pcR3-
mTRAIL-R plasmid, a kind gift of Dr. Micheau (Uni-
versity of Bourgogne Franche-Comté, Dijon, France). The
sequence was cloned into pENTR3C using the CloneEZ
PCR Cloning Kit (GenScript, Piscataway, NJ, USA), and
substitution of the Asparagine residues into Glutamine
residues was achieved by QuikChange® Site-Directed
Mutagenesis Kit (Agilent, Santa Clara, US). Sequences
were then transferred into pcDNA3, and custom-made
doxycyline-inducible pDG2(blast)-rtTA3-FLAG lentiviral
destination vectors46 using the LR Gateway recombina-
tion system (Life Technologies, Carlsbad, CA, USA).
Transient overexpression of mTRAIL-R mutants in Trail-
R−/−MEFs was done by transfection of pcDNA3 plasmids
using JetPRIME® transfection reagent (Polyplus-trans-
fection® SA, Illkirch, France), following the manu-
facturer’s recommendations. mTRAIL-R reconstitutions
were also achieved by lentiviral transduction. Viral parti-
cles were produced by transfecting HEK293T cells using
calcium phosphate with a pDG2(blast)-rtTA3-FLAG
vector containing the different forms of mTRAIL-R,
together with the lentiviral viral packaging vectors pMD2-
VSVG and pCMV-ΔR8.9.1. The medium was changed
after 6 h, and the virus-containing supernatant was col-
lected after 24 and 48 h and used to transduce the Trail-
R−/− MEFs. Stable reconstituted Trail-R−/− MEFs were
positively selected for 2 days by the addition of blasticidin
(10 µg/ml) in the cell culture medium.
Reagents and antibodies
Recombinant mouse SuperKillerTRAIL™ (mTRAIL-SK)
(ALX-201-130-C020), mTRAIL (BML-SE722-0100), and
human TRAIL-SK (ALX-201-115) were purchased from
Enzo Life Sciences GmbH (Lörrach, Germany).
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Tunicamycin (#T7765), thapsigargin (#T9033), and bre-
feldin A (#B7651) were obtained from Sigma-Aldrich (St.
Louis, MO, USA), and used at 1 µg/ml, 1 µM, and 0.5 µM,
respectively, unless stated otherwise. Kifunensine
(#K1140) and swainsonine (#S9263) were from Sigma. Z-
VAD-fmk (Bachem, Bubendorf, Switzerland; #N-1510)
was used at 20 µM. Recombinant human TNF was pro-
duced in our laboratory, puriﬁed to at least 99% homo-
geneity, had a speciﬁc biological activity of 3–107 IU/mg,
and was used at 600 IU/ml (20 ng/ml). Cycloheximide was
from Sigma-Aldrich (#C7698). PNGase F was a kind gift
of Prof. Dr. Nico Callewaert (VIB-UGent, Center of
Medical Biotechnology, Gent, Belgium). Biotin-
IsoLeucine Zipper (Biot-ILZ)-hTRAIL was produced in
the lab of Prof. MacFarlane (MRC Toxicology Unit, Lei-
cester, United Kingdom). Antibodies were purchased
from the following companies: anti-spliced Xbp-1 (Bio-
Legend, San Diego, CA, USA; #619501), anti-CHOP (Cell
Signaling, Danvers, MA, USA; #2895S), anti-Bip
(BDTransduction Laboratories, San Jose, CA, USA;
#610978), anti-caspase-8 (Abnova, Jhongli, Taiwan;
#MAB3429), anti-cleaved caspase-8 (Cell Signaling;
#9429), anti-caspase-3 (Cell Signaling; #9662), anti-β-
tubulin (Abcam, Cambridge, UK; #ab6046-200), anti-
cFLIP (Adipogen, San Diego, CA, USA; #AG-20B-0005),
anti-mTRAIL-R (Santa Cruz Biotechnology, Dallas, TX,
USA; #sc-57086), anti-FADD (Enzo #ADI-AAM-212),
phospho-p65 (Cell Signaling; #3033), p65 (Cell Signaling;
#8242), phospho-ERK (Cell Signaling; #9101), ERK (Cell
Signaling; #4696), phospho-IκB (Cell Signaling; #9246),
IκB (Cell Signaling; #7814, and Santa Cruz Biotechnology,
#sc-371), phospho-MK2 (Cell Signaling, #3007), and MK2
(Cell Signaling, #3042). Unless stated otherwise in the
ﬁgure legends, all immunoblots were performed in
reducing conditions.
Analysis of cell death and caspase-3 activity
Cell death and caspase-3-like activity were analyzed
using the Fluostar Omega ﬂuorescent plate reader (BMG
Labtech GmbH, Ortenberg, Germany) as previously
described47. Brieﬂy, the cells were seeded in 96-well plates
and were then treated with the indicated compounds in
the presence of 5 µM SYTOX Green (SG) (Life Tech-
nologies) and in absence or presence of 20 µM DEVD-
AMC (PeptaNova GmbH, Sandhausen, Germany). The
maximal SG ﬂuorescence was achieved by full permea-
bilization of the cells using 0.05% Triton X-100, and the
percentage of cell death was calculated as (induced SG
ﬂuorescence−background SG ﬂuorescence)/(maximal SG
ﬂuorescence−background SG ﬂuorescence)×100. Cell
death was also analyzed with an Incucyte ZOOM® system
(Essen BioScience, Michigan, USA) analyzing SG positive
cells. The 100% SG-positive cells were achieved by per-
meabilization of the cells using 0.02% Triton X-100. For
some experiments, death of mTRAIL-R-positive cells was
analyzed by ﬂow cytometry. In this case, cells were
resuspended in Annexin V-binding buffer containing
Annexin V-APC (BD Biosciences, San Jose, CA, USA) and
SYTOX Blue (Life Technologies) shortly before analysis
by ﬂow cytometry (FACSVerse, Becton Dickinson,
Franklin Lakes, NJ, USA). The data were then analyzed
using FlowJo software. Expression of the different indu-
cible forms of mTRAIL-R was induced 24 h prior to cell
death analysis by addition of doxycycline at the con-
centrations indicated in the ﬁgures.
PNGase F and EndoH digestions
Cells were lysed in Laemmli’s buffer and the proteins
were precipitated by adding two volumes of ice-cold 100%
acetone for 30min at 4 °C. Samples were then centrifugated
at 13,000 × g for 5min and the supernatant was discarded.
Pellets were resuspended in water and denaturated using
Glycoprotein Denaturing Buffer (New England BioLabs,
Ipswich, MA, USA). PNGase F or EndoH (#P0702, New
England BioLabs) was added or not, and the samples were
incubated at 37 °C for 1 h. For some experiments, rapid
PNGase F non-reducing format (#P0711, New England
BioLabs) was used. Brieﬂy, proteins were precipitated as
above and pellets were resuspended in water-containing
Rapid PNGase F (non-reducing format) buffer, and then
incubated 5min at 75 °C. Rapid PNGase F (non-reducing
format) was added, and the samples incubated at 50 °C for
10min. Laemmli’s buffer was added and the samples were
boiled before analysis by immunoblots.
Cell surface expression of mTRAIL-R
Plasma membrane expression of mTRAIL-R was
achieved by ﬂow cytometry. Cells were harvested and
resuspended in cold PBS containing 0.5% FCS. The cells
were then incubated in PBS-0.5% FCS containing anti-
mTRAIL-R-PE (eBioscience, San Diego, CA, USA; # 12-
5883) or isotype control at 4 °C for 30 min. Cells were
then washed three times in cold PBS-0.5% FCS before
analysis by the cytometer (FACSVerse). The data were
then analyzed using FlowJo software.
FADD immunoprecipitation
Following stimulation, cells were washed with cold PBS
and then lysed in cold lysis buffer (10 mM Tris-HCl
(pH7.5), 150 mM NaCl, 1% NP-40, and 10% glycerol),
supplemented with EDTA-free protease inhibitor cocktail
tablets (Roche Diagnostics, Basel, Switzerland) and
phosphatase inhibitor cocktail tablets (Roche Diag-
nostics). Endogenous FADD was immunoprecipitated
from the cleared lysates overnight at 4 °C using anti-
FADD antibody (Santa Cruz Biotechnology, Dallas, TX,
USA; #sc-6036) coupled to G beads. The beads were then
recovered by centrifugation, and immunoprecipitates
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were washed three times in cold lysis buffer before elution
in Laemmli’s buffer. Immunoprecipitates were then ana-
lyzed by immunoblots performed in reducing condition
unless stated otherwise in the ﬁgure legends.
mTRAIL-R pulldown assay
Strep-pulldown assay was performed as previously
described48. Brieﬂy, cells were seeded in 150mm dishes,
and treated or not the day after with TU for 7 h. The cells
were then pre-cooled at 4 °C before adding Biot-ILZ
hTRAIL at 500 ng/ml for 45min at 4 °C to facilitate
“loading” of TRAIL-R. The cells were switched to 37 °C
for 15min and then immediately washed with cold PBS
and lysed in cold lysis buffer (30 mM Tris/HCl (pH 7.5),
150mM NaCl, 10% glycerol, 1% Triton X-100) supple-
mented with EDTA-free protease inhibitors (Roche
Diagnostics). Biot-ILZ hTRAIL-bound complexes were
precipitated using streptavidin magnetic beads (Dyna-
beadsTM M-280 Streptavidin, Thermo Fisher Scientiﬁc,
Waltham, MA USA) overnight at 4 °C. Beads were then
washed three times with cold lysis buffer, and complexes
eluted in Laemmli’s buffer before analysis by immunoblot.
For His-Tag pulldown, cells were seeded and treated with
TU as above. Cells were harvested, resuspended in 1ml
medium, and let recover for 30min. Cells were then
treated for increasing times with 500 ng/ml mTRAIL SK
at 37 °C, washed with cold PBS, and lysed as above.
mTRAIL SK-bound complexes were precipitated using
His-Tag DynabeadsTM magnetic beads (Thermo Fisher
Scientiﬁc) overnight at 4 °C, and complexes eluted in
Laemmli’s buffer before analysis by immunoblots per-
formed in reducing condition unless stated otherwise in
the ﬁgure legends.
Statistical analysis
Unless stated otherwise, two-tailed unpaired t-test was
used for statistical analysis. *P < 0.05 and **P < 0.01 were
considered as signiﬁcant.
Acknowledgements
We thank Prof. Savvides (VIB/UGent, Belgium) and Prof. Callewaert (VIB/UGent,
Belgium) for insightful discussions, and Béatrice Vanbervliet for her assistance
in cell culture. We are grateful to Prof. Mak (University of Toronto, Canada) for
the mTRAIL-R-deﬁcient MEFs. Research in the groups of Prof. M. Bertrand and
Prof. P. Vandenabeele is supported by grants from the Vlaams Instituut voor
Biotechnologie (VIB), grants from Ghent University (MRP, GROUP-ID
consortium), grants from the Fonds voor Wetenschappelijk Onderzoek
Vlaanderen (FWO) (G017212N, G013715N, G078713N), from the Flemish
Government (Methusalem BOF09/01M00709 and BOF16/MET_V/007), and
from the Belgian science policy ofﬁce (BELSPO) (IAP 7/32). Dr. Dondelinger is
holder of a FWO postdoctoral fellowship. Research in the group of Prof. S.
Lebecque is supported by grants from the Cancéropôle Lyon Auvergne Rhône
Alpes, France (PDC 016 CITCAP CLARA, Lyon) and from the Institut National de
la Recherche contre le Cancer (INCA) France (PAIR CHC 2009-140).
Author details
1VIB Center for Inﬂammation Research, Technologiepark 927, Zwijnaarde-
Ghent 9052, Belgium. 2Department of Biomedical Molecular Biology, Ghent
University, Technologiepark 927, Zwijnaarde-Ghent 9052, Belgium. 3Université
Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre
de Recherche en Cancérologie de Lyon, Lyon F-69373, France. 4MRC
Toxicology Unit, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK.
5Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d’Anatomie
Pathologique, 69495 Pierre Bénite Cedex, France
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at https://doi.org/
10.1038/s41419-018-0544-7.
Received: 16 October 2017 Revised: 21 March 2018 Accepted: 30 March
2018
References
1. Ashkenazi, A. & Salvesen, G. Regulated cell death: signaling and mechanisms.
Annu. Rev. Cell Dev. Biol. 30, 337–356 (2014).
2. MacFarlane, M. et al. Identiﬁcation and molecular cloning of two novel
receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272, 25417–25420
(1997).
3. Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113
(1997).
4. Schneider, P. et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-
dependent apoptosis and activate NF-kappaB. Immunity 7, 831–836 (1997).
5. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling
and decoy receptors. Science 277, 818–821 (1997).
6. Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5
monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7,
954–960 (2001).
7. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apop-
tosis-inducing ligand in vivo. Nat. Med. 5, 157–163 (1999).
8. Dimberg, L. Y. et al. On the TRAIL to successful cancer therapy? Predicting and
counteracting resistance against TRAIL-based therapeutics. Oncogene 32,
1341–1350 (2013).
9. de Miguel, D., Lemke, J., Anel, A., Walczak, H. & Martinez-Lostao, L. Onto better
TRAILs for cancer treatment. Cell Death Differ. 23, 733–747 (2016).
10. Wiezorek, J., Holland, P. & Graves, J. Death receptor agonists as a targeted
therapy for cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 16, 1701–1708
(2010).
11. Peter, M. E. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Differ. 7,
759–760 (2000).
12. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting
protein, mediates cytochrome c release from mitochondria in response to
activation of cell surface death receptors. Cell 94, 481–490 (1998).
13. Ozoren, N. & El-Deiry, W. S. Deﬁning characteristics of Types I and II apoptotic
cells in response to TRAIL. Neoplasia 4, 551–557 (2002).
14. Rudner, J. et al. Type I and type II reactions in TRAIL-induced apoptosis --
results from dose-response studies. Oncogene 24, 130–140 (2005).
15. Kim, Y. S., Schwabe, R. F., Qian, T., Lemasters, J. J. & Brenner, D. A. TRAIL-
mediated apoptosis requires NF-kappaB inhibition and the mitochondrial
permeability transition in human hepatoma cells. Hepatology 36, 1498–1508
(2002).
16. Kreuz, S., Siegmund, D., Scheurich, P. & Wajant, H. NF-kappaB inducers upre-
gulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Mol. Cell. Biol. 21, 3964–3973 (2001).
17. Bin, L., Li, X., Xu, L. G. & Shu, H. B. The short splice form of Casper/c-FLIP is a
major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett. 510, 37–40
(2002).
18. Geserick, P. et al. Suppression of cFLIP is sufﬁcient to sensitize human mela-
noma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27,
3211–3220 (2008).
Estornes et al. Cell Death and Disease  (2018) 9:494 Page 12 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
19. Kim, Y., Suh, N., Sporn, M. & Reed, J. C. An inducible pathway for degradation
of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem.
277, 22320–22329 (2002).
20. Wagner, K. W. et al. Death-receptor O-glycosylation controls tumor-cell sen-
sitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13, 1070–1077
(2007).
21. Walter, P. & Ron, D. The unfolded protein response: from stress pathway to
homeostatic regulation. Science 334, 1081–1086 (2011).
22. Chen, L. H. et al. Thapsigargin sensitizes human melanoma cells to TRAIL-
induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein
response. Carcinogenesis 28, 2328–2336 (2007).
23. He, Q. et al. Endoplasmic reticulum calcium pool depletion-induced apoptosis
is coupled with activation of the death receptor 5 pathway. Oncogene 21,
2623–2633 (2002).
24. Jiang, C. C. et al. Tunicamycin sensitizes human melanoma cells to tumor
necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-
regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67,
5880–5888 (2007).
25. Jin, Z., McDonald, E. R. 3rd, Dicker, D. T. & El-Deiry, W. S. Deﬁcient tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) death recep-
tor transport to the cell surface in human colon cancer cells selected
for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279,
35829–35839 (2004).
26. Jung, Y. H., Lim, E. J., Heo, J., Kwon, T. K. & Kim, Y. H. Tunicamycin
sensitizes human prostate cells to TRAIL-induced apoptosis by upre-
gulation of TRAIL receptors and downregulation of cIAP2. Int. J. Oncol.
40, 1941–1948 (2012).
27. Martin-Perez, R., Niwa, M. & Lopez-Rivas, A. ER stress sensitizes cells to TRAIL
through down-regulation of FLIP and Mcl-1 and PERK-dependent up-reg-
ulation of TRAIL-R2. Apoptosis 17, 349–363 (2012).
28. Shiraishi, T. et al. Tunicamycin enhances tumor necrosis factor-related apop-
tosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Cancer Res. 65, 6364–6370 (2005).
29. Cazanave, S. C. et al. Death receptor 5 signaling promotes hepatocyte lipoa-
poptosis. J. Biol. Chem. 286, 39336–39348 (2011).
30. Dufour, F. et al. TRAIL receptor gene editing unveils TRAIL-R1 as a master
player of apoptosis induced by TRAIL and ER stress. Oncotarget 8, 9974–9985
(2017).
31. Li, T. et al. DDIT3 and KAT2A proteins regulate TNFRSF10A and TNFRSF10B
expression in endoplasmic reticulum stress-mediated apoptosis in human
lung cancer cells. J. Biol. Chem. 290, 11108–11118 (2015).
32. Lu, M. et al. Opposing unfolded-protein-response signals converge on death
receptor 5 to control apoptosis. Science 345, 98–101 (2014).
33. Estornes, Y. et al. RIPK1 promotes death receptor-independent caspase-8-
mediated apoptosis under unresolved ER stress conditions. Cell Death Dis. 5,
e1555 (2014).
34. Charlier, E. et al. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary
T lymphocytes and T leukemic cells by promoting CD95 glycosylation inde-
pendently of its phosphatase activity. Leukemia 24, 821–832 (2010).
35. Peter, M. E. et al. Cell surface sialylation plays a role in modulating sensitivity
towards APO-1-mediated apoptotic cell death. Cell Death Differ. 2, 163–171
(1995).
36. Swindall, A. F. & Bellis, S. L. Sialylation of the Fas death receptor by ST6Gal-I
provides protection against Fas-mediated apoptosis in colon carcinoma cells.
J. Biol. Chem. 286, 22982–22990 (2011).
37. Caramelo, J. J. & Parodi, A. J. A sweet code for glycoprotein folding. FEBS Lett.
589, 3379–3387 (2015).
38. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum.
Annu. Rev. Biochem. 73, 1019–1049 (2004).
39. Hirabayashi, J. et al. Oligosaccharide speciﬁcity of galectins: a search by frontal
afﬁnity chromatography. Biochim. Et Biophys. Acta 1572, 232–254 (2002).
40. Mazurek, N. et al. Cell-surface galectin-3 confers resistance to TRAIL by
impeding trafﬁcking of death receptors in metastatic colon adenocarcinoma
cells. Cell Death Differ. 19, 523–533 (2012).
41. Yoshida, T., Shiraishi, T., Horinaka, M., Wakada, M. & Sakai, T. Glycosylation
modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-
apoptotic receptors for TRAIL by tunicamycin. Oncol. Rep. 18, 1239–1242 (2007).
42. Dufour, F. et al. N-glycosylation of mouse TRAIL-R and human TRAIL-R1
enhances TRAIL-induced death. Cell Death Differ. 24, 500–510 (2017).
43. Shatnyeva, O. M. et al. Modulation of the CD95-induced apoptosis: the role of
CD95 N-glycosylation. PLoS ONE 6, e19927 (2011).
44. Keppler, O. T. et al. Differential sialylation of cell surface glycoconjugates in a
human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-
mediated apoptosis and for infection by a lymphotropic virus. Glycobiology 9,
557–569 (1999).
45. Dondelinger, Y. et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-
dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase
inhibition. Cell Death Differ. 20, 1381–1392 (2013).
46. De Groote, P. et al. Generation of a new Gateway-compatible inducible len-
tiviral vector platform allowing easy derivation of co-transduced cells. Bio-
Techniques 60, 252–259 (2016).
47. Grootjans, S. et al. A real-time ﬂuorometric method for the simultaneous
detection of cell death type and rate. Nat. Protoc. 11, 1444–1454 (2016).
48. Hughes, M. A., Langlais, C., Cain, K. & MacFarlane, M. Isolation, characterisation
and reconstitution of cell death signalling complexes. Methods 61, 98–104
(2013).
Estornes et al. Cell Death and Disease  (2018) 9:494 Page 13 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
